Most recurrences occurred in patients who had received prior chemotherapy , among whom the rate of freedom from breast cancer at 5 years was 82.5 % in the tamoxifen-ovarian suppression group and 78.0 % in the tamoxifen group ( hazard ratio for recurrence , 0.78 ; 95 % CI , 0.60 to 1.02 ) .